Can age‑related macular degeneration be asymptomatic?

Can Age-Related Macular Degeneration Be Asymptomatic?

Yes, early age-related macular degeneration is typically asymptomatic, making regular comprehensive eye examinations essential for detection in at-risk populations. 1

Clinical Presentation by Disease Stage

Early AMD

• Early AMD is characteristically asymptomatic, with patients experiencing no visual complaints despite the presence of medium-sized drusen and retinal pigmentary changes 1, 2
• Traditional suprathreshold clinical tests often fail to reveal functional deficiencies at this stage, though subtle changes in tolerance to stimulus degradation may be present 3
• The asymptomatic nature of early disease can delay treatment until progression occurs, which is why screening in specific contexts serves as a critical early detection tool 4

Intermediate AMD

• Intermediate AMD, characterized by large drusen (≥125 μm) and retinal pigment epithelium clumping or atrophy, may remain asymptomatic or present with only mild visual symptoms 1, 5
• Patients at this stage typically do not report visual complaints severe enough to prompt evaluation, yet they face significant risk of progression to vision-threatening late AMD 5

Late AMD

• Late AMD (both neovascular and geographic atrophy) typically presents with severe and often irreversible visual symptoms, including profoundly decreased central vision, blurred vision, metamorphopsia (distorted vision), and central vision loss 1, 6
• However, even at advanced stages, the fellow eye of patients with unilateral wet AMD may harbor asymptomatic choroidal neovascularization that requires detection through regular monitoring 1

Critical Clinical Implications

Importance of Screening

• The American Academy of Ophthalmology recommends regular comprehensive eye examinations for early detection, as early symptoms may be subtle and early treatment is associated with more favorable prognosis 1
• For patients with wet AMD in one eye, the fellow eye remains at exceptionally high risk and should be monitored every 6-12 months even without symptoms to detect asymptomatic choroidal neovascularization at a treatable stage 1

Risk Stratification for Asymptomatic Patients

• Patients with high-risk features—bilateral soft drusen, confluent drusen, RPE clumping or atrophy, and family history—require AREDS2 supplementation even when asymptomatic, as this reduces progression risk by up to 36% over 10 years 1, 2
• Age is the dominant risk factor, with AMD prevalence increasing from 1% in those aged 65-69 years to 17% in those older than 80 years, making routine screening essential in older adults 2

Patient Education for Self-Monitoring

• Provide an Amsler grid for daily home monitoring of metamorphopsia, with instructions to return immediately for any new visual symptoms 2
• Patients should be instructed to look at the central dot and evaluate if any grid lines appear wavy or distorted, as this may indicate progression from asymptomatic to symptomatic disease 1

Common Pitfalls to Avoid

• Do not wait for visual complaints before evaluating for AMD in at-risk populations, as the disease is typically asymptomatic in early stages when intervention is most effective 1, 2
• Do not assume that normal visual acuity excludes AMD, as early disease may not directly affect suprathreshold visual functions when stimuli contain redundant information 3
• For patients with advanced AMD in one eye and large drusen with RPE changes in the fellow eye, do not rely solely on symptom reporting—this represents the highest risk group requiring regular monitoring even without symptoms 1